WallachBeth Capital Announces Closing of bioAffinity Technologies $2.6 Million Registered Direct Offering & Concurrent Private Placement

Core Viewpoint - bioAffinity Technologies, Inc. has successfully closed a registered direct offering and concurrent private placement, raising gross proceeds of $2,662,782 through the sale of common stock and warrants [1][2]. Group 1: Offering Details - The offering included 2,048,294 shares of common stock priced at $1.30 per share and warrants to purchase up to 2,662,782 shares at an exercise price of $1.50 per share [1]. - The warrants will be exercisable upon stockholder approval and will expire five years from the date of such approval [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, including working capital [2]. Group 3: Regulatory Compliance - The shares were issued under an effective shelf registration statement filed with the SEC, and a prospectus supplement will be available on the SEC's website [3]. - The private placement of the warrants is made under an exemption from registration, meaning they cannot be offered or sold in the U.S. without an effective registration statement or applicable exemption [3]. Group 4: Company Background - WallachBeth Capital LLC acted as the sole placement agent for the offering, providing a range of capital markets and investment banking services to the healthcare sector [5].